{
    "id": "ckd_erythropoietin_clozeDropdown_v1",
    "type": "clozeDropdown",
    "stem": "Complete the teaching for a client with Chronic Kidney Disease (CKD) on Epoetin Alfa.",
    "template": "A client on erythropoiesis-stimulating agents (ESAs) should be monitored for the complication of {{complication}}. The nurse should prioritize checking {{vitalsign}} before administering the subcutaneous injection.",
    "blanks": [
        {
            "id": "complication",
            "options": [
                "Hypertension and Thrombosis",
                "Hypokalemia",
                "Prolonged bleeding time"
            ],
            "correctOption": "Hypertension and Thrombosis"
        },
        {
            "id": "vitalsign",
            "options": [
                "Blood Pressure",
                "Heart Rate",
                "Symmetry of pulses"
            ],
            "correctOption": "Blood Pressure"
        }
    ],
    "pedagogy": {
        "bloomLevel": "analyze",
        "cjmmStep": "evaluateOutcomes",
        "nclexCategory": "Pharmacological and Parenteral Therapies",
        "difficulty": 3,
        "topicTags": [
            "Renal",
            "Hematology",
            "Pharmacology"
        ]
    },
    "rationale": {
        "correct": "Epoetin alfa increases red blood cell production, which increases blood viscosity. This leads to Hypertension (most common side effect) and an increased risk for stroke or MI (Thrombosis). If BP is severely elevated, the dose should be held.",
        "incorrect": "ESA does not affect potassium or coagulation factors (bleeding).",
        "answerBreakdown": [
            {
                "label": "Blank 1",
                "content": "The selection of \"Hypertension and Thrombosis\" correctly completes the clinical hypothesis based on assessment cues.",
                "isCorrect": true
            },
            {
                "label": "Blank 2",
                "content": "The selection of \"Blood Pressure\" correctly completes the clinical hypothesis based on assessment cues.",
                "isCorrect": true
            }
        ],
        "clinicalPearls": [
            "Epoetin alfa should be held if the Hemoglobin level is >11 g/dL due to the significantly increased risk of cardiovascular events."
        ],
        "questionTrap": {
            "trap": "The 'Iron' Link",
            "howToOvercome": "Remember that if the patient's iron stores are low, Epoetin Alfa won't work. They often need supplemental iron alongside ESA therapy."
        },
        "mnemonic": {
            "title": "E-P-O",
            "expansion": "Elevates (Hemoglobin), Pressure (Increases), Out (of range if Hgb >11)."
        },
        "reviewUnits": [
            {
                "heading": "Anemia Management in Chronic Kidney Disease",
                "body": "Nurses monitor Hgb/Hct every 2-4 weeks. The goal is to avoid blood transfusions, not to reach 'normal' non-CKD hemoglobin levels.",
                "source": "KDIGO: Clinical Practice Guidelines"
            }
        ]
    },
    "scoring": {
        "method": "polytomous",
        "maxPoints": 2
    }
}